Inghams Group (ING) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
14 Jan, 2026Opening remarks and agenda
Meeting opened with acknowledgment of traditional land owners and an outline of the agenda, including addresses from the Chair and CEO, formal business, and Q&A.
Voting conducted by poll, with both in-person and virtual participation options and clear instructions provided.
Board members, leadership team, and external auditor introduced; auditor available for questions on audit matters.
Financial performance review
Achieved record FY24 results: revenue of $3,262.0M (+7.2%), underlying EBITDA of $240.1M (+30.8%), and net profit after tax of $101.5M (+68.0%).
Group core poultry volume reached 476.4KT, up 2.8%, with New Zealand volume growth at 8.4% and Australia at 1.9%.
Dividends per share increased to 20.0 cents (+37.9%), with a payout ratio of 73.1%.
FY25 guidance reaffirmed: underlying EBITDA expected at $236–$250M, flat to ~6% growth on normalised FY24.
FY25 YTD group core poultry volume down 4.0% vs 1H24, but up 1.9% vs 2H24; net selling price stable at $6.28/kg.
Board and executive committee updates
Board composition highlighted, including committee chairs, recent appointments, and leadership stability.
Linda Bardo Nicholls stood for re-election, with the board unanimously supporting her continuation.
Latest events from Inghams Group
- AUD 130 million EBITDA uplift targeted through operational, digital, and value-led improvements.ING
Investor Day 2026 - EBITDA and profit dropped on flat revenue, but cost actions set up a stronger second half.ING
H1 2026 - Stable EBITDA, leadership refresh, and cost-out program set the stage for FY26 improvements.ING
AGM 2025 - Stable EBITDA and strong NZ growth offset Australian softness; FY26 targets cost-out and automation.ING
H2 2025 - Record FY24 earnings and margins; FY25 outlook stable despite volume headwinds.ING
H2 2024 - EBITDA near record, NZ growth and cost control offset lower volumes; FY25 guidance reaffirmed.ING
H1 2025